费城阳性急性淋巴细胞白血病中 mini-hyper-CVD、blinatumomab 和 ponatinib 的 2 期试验。
A phase 2 trial of mini-hyper-CVD, blinatumomab, and ponatinib in Philadelphia positive acute lymphoblastic leukemia.
机构信息
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
出版信息
Am J Hematol. 2024 Nov;99(11):2229-2232. doi: 10.1002/ajh.27463. Epub 2024 Aug 28.
Abstract
Twenty adults with newly diagnosed (ND) or relapsed/refractory (RR) Ph-positive acute lymphoblastic leukemia (ALL), or chronic myeloid leukemia in lymphoid blast phase (CML-LBP), were treated with mini-hyperCVD, ponatinib, and blinatumomab. Complete molecular response was achieved in 78% of ND patients, while CR/CRi was achieved in 100% of RR and CML-LBP. The 3-year overall survival rate was 76% (95% CI, 47%-90%).
摘要
20 例新诊断（ND）或复发/难治（RR）Ph 阳性急性淋巴细胞白血病（ALL）或慢性髓性白血病急淋变（CML-LBP）患者接受 mini-hyperCVD、ponatinib 和 blinatumomab 治疗。ND 患者中 78%达到完全分子缓解，RR 和 CML-LBP 患者中 100%达到 CR/CRi。3 年总生存率为 76%（95%CI，47%-90%）。
相似文献
1
A phase 2 trial of mini-hyper-CVD, blinatumomab, and ponatinib in Philadelphia positive acute lymphoblastic leukemia.费城阳性急性淋巴细胞白血病中 mini-hyper-CVD、blinatumomab 和 ponatinib 的 2 期试验。
Am J Hematol. 2024 Nov;99(11):2229-2232. doi: 10.1002/ajh.27463. Epub 2024 Aug 28.
2
Results of the Simultaneous Combination of Ponatinib and Blinatumomab in Philadelphia Chromosome-Positive ALL.波纳替尼与博纳吐单抗联合用于费城染色体阳性急性淋巴细胞白血病的疗效
J Clin Oncol. 2024 Dec 20;42(36):4246-4251. doi: 10.1200/JCO.24.00272. Epub 2024 Jul 19.
3
Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial.帕纳替尼和blinatumomab 治疗费城染色体阳性急性淋巴细胞白血病：美国单中心、单臂、2 期临床试验。
Lancet Haematol. 2023 Jan;10(1):e24-e34. doi: 10.1016/S2352-3026(22)00319-2. Epub 2022 Nov 16.
4
Quality-Adjusted Time Without Symptoms of Disease or Toxicity (Q-TWiST) in Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Comparison of Ponatinib Versus Imatinib.初诊费城染色体阳性急性淋巴细胞白血病患者无疾病或毒性症状的质量调整时间（Q-TWiST）：波纳替尼与伊马替尼的比较
Cancer Med. 2025 Apr;14(7):e70780. doi: 10.1002/cam4.70780.
5
Molecular characterization and predictors of relapse in patients with Ph + ALL after frontline ponatinib and blinatumomab.一线使用波纳替尼和博纳吐单抗治疗后Ph+急性淋巴细胞白血病患者的分子特征及复发预测因素
J Hematol Oncol. 2025 May 14;18(1):55. doi: 10.1186/s13045-025-01709-y.
6
Ponatinib: A new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.普纳替尼：一种新型酪氨酸激酶抑制剂，用于治疗慢性髓性白血病和费城染色体阳性急性淋巴细胞白血病。
Ann Pharmacother. 2013 Nov;47(11):1540-6. doi: 10.1177/1060028013501144. Epub 2013 Nov 21.
7
Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults.Blinatumomab 治疗成人 MRD 阴性急性淋巴细胞白血病。
N Engl J Med. 2024 Jul 25;391(4):320-333. doi: 10.1056/NEJMoa2312948.
8
Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study.Hyper-CVAD与波纳替尼联合作为费城染色体阳性急性淋巴细胞白血病患者的一线治疗：一项单中心2期研究。
Lancet Oncol. 2015 Nov;16(15):1547-1555. doi: 10.1016/S1470-2045(15)00207-7. Epub 2015 Sep 30.
9
[Successful treatment with sequential blinatumomab/ponatinib in a patient with chronic myeloid leukemia presenting with a CD19-positive mixed phenotype blast phase].[序贯使用博纳吐单抗/普纳替尼成功治疗一例呈现CD19阳性混合表型原始细胞期的慢性髓性白血病患者]
Rinsho Ketsueki. 2024;65(11):1375-1380. doi: 10.11406/rinketsu.65.1375.
10
Vodobatinib for patients with Philadelphia chromosome-positive chronic myeloid leukaemia resistant or intolerant to multiple lines of previous therapy: an open-label, multicentre, phase 1/2 trial.沃多替尼用于对多线既往治疗耐药或不耐受的费城染色体阳性慢性髓性白血病患者：一项开放标签、多中心、1/2期试验。
Lancet Haematol. 2025 Mar;12(3):e201-e213. doi: 10.1016/S2352-3026(24)00354-5. Epub 2025 Feb 7.
引用本文的文献
1
The evolving therapeutic revolution in adult acute lymphoblastic leukemia.成人急性淋巴细胞白血病不断发展的治疗革命。
Cancer. 2025 May 15;131(10):e35872. doi: 10.1002/cncr.35872.
本文引用的文献
1
Long-Term Results of the Dasatinib-Blinatumomab Protocol for Adult Philadelphia-Positive ALL.达沙替尼-blinatumomab 方案治疗成人费城阳性 ALL 的长期结果。
J Clin Oncol. 2024 Mar 10;42(8):881-885. doi: 10.1200/JCO.23.01075. Epub 2023 Dec 21.
2
Frontline combination of ponatinib and hyper-CVAD in Philadelphia chromosome-positive acute lymphoblastic leukemia: 80-months follow-up results.在费城染色体阳性急性淋巴细胞白血病中，帕纳替尼联合超 CVAD 的一线治疗：80 个月随访结果。
Am J Hematol. 2023 Mar;98(3):493-501. doi: 10.1002/ajh.26816. Epub 2023 Jan 4.
3
Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial.帕纳替尼和blinatumomab 治疗费城染色体阳性急性淋巴细胞白血病：美国单中心、单臂、2 期临床试验。
Lancet Haematol. 2023 Jan;10(1):e24-e34. doi: 10.1016/S2352-3026(22)00319-2. Epub 2022 Nov 16.
4
Ponatinib, chemotherapy, and transplant in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.帕纳替尼、化疗和移植治疗费城染色体阳性急性淋巴细胞白血病成人患者。
Blood Adv. 2022 Sep 27;6(18):5395-5402. doi: 10.1182/bloodadvances.2022007764.
5
Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study.依妥珠单抗奥滨尤妥珠单抗与低强度化疗联合用于费城染色体阴性的老年急性淋巴细胞白血病患者：一项单臂、2 期研究。
Lancet Oncol. 2018 Feb;19(2):240-248. doi: 10.1016/S1470-2045(18)30011-1. Epub 2018 Jan 16.
6
Monitoring of childhood ALL using genomic breakpoints identifies a subgroup with CML-like biology.利用基因组断点监测儿童 ALL 可识别出具有 CML 样生物学特性的亚组。
Blood. 2017 May 18;129(20):2771-2781. doi: 10.1182/blood-2016-11-749978. Epub 2017 Mar 22.
Zotero 插件